"Keegan states that the valuation of Biotech companies is as
much an art as a science. This brief but comprehensive review of
the skills and knowledge required, not of just the financial market
and sentiment, but also of the technical attributes of a company
and the drug development and regulatory hurdles that must be
overcome, highlights the importance of the breadth of understanding
required. Biotech investing is not for the timid, but it can bring
substantial returns. Keegan's book, punctuated with his personal
experience and opinions, is a good place to start."
?Chris Blackwell, Chief Executive, Vectura Group plc
"A user-friendly, yet thorough discussion of a notoriously
difficult topic. Dr Keegan's book is a fine resource for both
business types and academicians."
?Steve Winokur, Managing Director, CanaccordAdams
"A highly readable and comprehensive explanation of the
technical and commercial parameters that influence biotechnology
companies at all stages of development, providing clear context for
selection from the toolkit of valuation methodologies the author
recommends to assess company and product performance, or ascribe
?Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge
"A fabulous approach to a difficult topic."
?Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company